Researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy. The findings, published in Science Translational Medicine and highlighted by Scientific American, indicate that the blood-brain barrier may remain compromised and permeable for decades following an athlete's retirement from contact sports.
When the integrity of the blood-brain barrier becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain. This neuroinflammation can trigger damaging processes, including the abnormal accumulation of tau protein, a hallmark indicator of CTE. Researchers observed that former athletes in the study appeared to exist in a persistent state of chronic hyperinflammation.
The Trinity study adds to growing evidence that systemic inflammation is a key driver of neuroinflammation associated with disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. This connection between bloodstream inflammation and brain disorders creates new therapeutic opportunities for technologies that can reduce systemic inflammation.
Sigyn Therapeutics, developer of CardioDialysis, disclosed that this scientific discovery supports the potential use of their blood purification technology to treat neuroinflammatory diseases. CardioDialysis enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. The Scientific American article detailing the blood-brain barrier research can be accessed at https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/.
"It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease," stated Sigyn Therapeutics CEO Jim Joyce. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain."
The company is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury. While the lead clinical indication remains cardiovascular disease, the technology's mechanism positions it as a potential adjunct therapy for various neuroinflammatory conditions. This development matters because it addresses a critical gap in treating neurodegenerative diseases, where current therapies often fail to address the underlying inflammatory processes that drive disease progression.
The implications extend beyond professional athletes to anyone experiencing repetitive head trauma or systemic inflammation. By potentially stabilizing the blood-brain barrier through reduction of inflammatory molecules in the bloodstream, this approach could slow disease progression in multiple neurological disorders. The research underscores the importance of addressing systemic inflammation as a therapeutic target, potentially transforming how neuroinflammatory conditions are managed and creating new hope for patients with limited treatment options.
